Literature DB >> 14717961

Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1).

H R Lijnen1, B Van Hoef, K Umans, D Collen.   

Abstract

The controversial role of plasminogen activator inhibitor-1 (PAI-1) in neointima formation and restenosis was studied with the use of a vascular injury model in transgenic mice overexpressing murine PAI-1 (PAI-1 Tg) and in wild-type (WT) controls. Despite the high circulating PAI-1 levels in the PAI-1 Tg mice (52 +/- 9.8 ng mL-1 vs. 0.76 +/- 0.17 ng mL-1 in WT mice), no significant fibrin deposition was observed in non-injured femoral arteries of 8- to 12-week-old mice. Two weeks after severe electric injury, extensive and comparable fibrin deposition was observed in both genotypes, despite a significantly reduced in situ fibrinolytic activity in arterial sections of the PAI-1 Tg mice. The neointimal and medial areas were similar in WT and PAI-1 Tg mice, resulting in comparable intima/media ratios (e.g. 0.94 +/- 0.25 and 1.04 +/- 0.17 at the center of the injury). Nuclear cell counts in cross-sectional areas of the neointima of the injured region were also comparable in arteries from WT and PAI-1 Tg mice (224 +/- 63, 233 +/- 20), and the distribution pattern of alpha-actin-positive smooth muscle cells was similar. These findings indicate that in a vascular injury model that induces extensive and persistent fibrin deposition in femoral arteries of mice, overexpression of PAI-1 does not affect neointima formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717961     DOI: 10.1111/j.1538-7836.2003.00533.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.

Authors:  N Garg; N Goyal; T L Strawn; J Wu; K M Mann; D A Lawrence; W P Fay
Journal:  J Thromb Haemost       Date:  2010-05-12       Impact factor: 5.824

2.  Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.

Authors:  Jianbo Wu; Lin Peng; Grainne A McMahon; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

Review 3.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

Authors:  Hunjoo Ha; Eun Y Oh; Hi B Lee
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

4.  Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts.

Authors:  Laura Carreras-Planella; David Cucchiari; Laura Cañas; Javier Juega; Marcella Franquesa; Josep Bonet; Ignacio Revuelta; Fritz Diekmann; Omar Taco; Ricardo Lauzurica; Francesc Enric Borràs
Journal:  J Nephrol       Date:  2020-12-04       Impact factor: 3.902

Review 5.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

6.  Gastric expression of plasminogen activator inhibitor (PAI)-1 is associated with hyperphagia and obesity in mice.

Authors:  Susan Kenny; Joanne Gamble; Suzanne Lyons; Nikolina Vlatkovic; Rod Dimaline; Andrea Varro; Graham J Dockray
Journal:  Endocrinology       Date:  2012-12-18       Impact factor: 4.736

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.